A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies

Overview

This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.

SparkCures ID 659
Trial Phase Phase 1
Enrollment 60 Patients
Treatments
  • APTO-253
Trial Sponsors
  • Aptose Biosciences
NCT Identifier

NCT02267863

CLOSED

This trial has terminated.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Male or female 18 years of age or older
  • Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed
  • Meet laboratory parameter requirements at study entry

Exclusion Criteria:

  • Pregnancy or breast feeding
  • History of prior malignancy
  • Auto-immune hemolytic anemia
  • Acute Promyelocytic Leukemia
  • Uncontrolled and clinically significant disease-related metabolic disorder
  • Other serious illness or medical conditions
  • Patients who have exhibited allergic reactions to compounds structurally similar to APTO-253 HCl

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers